<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04555694</url>
  </required_header>
  <id_info>
    <org_study_id>TC-2020-DexRes</org_study_id>
    <nct_id>NCT04555694</nct_id>
  </id_info>
  <brief_title>Comparing Treatment of Dry Eye With Intracanlicular Dexamethasone, Restasis, and/or Lotemax</brief_title>
  <official_title>Intracanalicular Dexamethasone Used in Conjunction With Restasis (Cyclosporine Ophthalmic Emulsion) for the Treatment of Signs and Symptoms of Dry Eye Disease as Compared to Restasis With Lotemax (Loteprednol Etabonate Ophthalmic Suspension 0.5%) and Restasis Monotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Chester, OD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cleveland Eye Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This 6 month study seeks to compare the use of Intracanalicular Dexamethasone in conjunction&#xD;
      with Restasis (cyclosporine ophthalmic emulsion) for the treatment of signs and symptoms of&#xD;
      dry eye disease as compared to Restasis with Lotemax (loteprednol etabonate ophthalmic&#xD;
      suspension 0.5%) and Restasis monotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>10 subjects will receive Restasis and Dextenza 10 subjects will receive Restasis and Lotemax 10 subjects will receive Restasis</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in ocular surface staining</measure>
    <time_frame>Week 1 to week 12</time_frame>
    <description>Mean change in ocular surface staining measured by the NEI grading scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in MMP-9</measure>
    <time_frame>Week 1 to week 12</time_frame>
    <description>Change in MMP-9 measured by InflammaDry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in tear break-up time (TBUT)</measure>
    <time_frame>Week 1 to week 12</time_frame>
    <description>Change in tear break-up time (TBUT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in conjunctival injection</measure>
    <time_frame>Week 1 to week 12</time_frame>
    <description>Change in conjunctival injection measured on a scale of 0-4 and graded by physician</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in meibomian gland scores</measure>
    <time_frame>Week 1 to week 12</time_frame>
    <description>Meibomian gland scores through expression and quality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in tear osmolarity</measure>
    <time_frame>Week 1 to week 12</time_frame>
    <description>Change in tear osmolarity as measured by Tear Lab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in DEQ-5</measure>
    <time_frame>Week 1 to week 12</time_frame>
    <description>Change in DEQ-5 as patient reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in Best-corrected Visual Acuity (BCVA</measure>
    <time_frame>Week 1 to Week 12</time_frame>
    <description>Chnage in best-corrected visual acuity measured by ETDRS chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in Schirmer's score</measure>
    <time_frame>Week 4 to Week 12</time_frame>
    <description>Change in Schirmer's score measured by Schirmer's test strip</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>Restasis and Lotemax</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 subjects will be receiving Restasis ophthalmic solution twice a day in both eyes and Lotemax ophthalmic solution twice a day in both eyes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Restasis and Dextenza</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 subjects will be receiving Restasis ophthalmic solution twice a day in both eyes, as well as receiving Dextenza insertion in both lower lids.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Restasis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 subjects will be receiving Restasis ophthalmic solution twice a day in both eyes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporin</intervention_name>
    <description>Used to increase tear production in patients who have dry eye caused by inflammation</description>
    <arm_group_label>Restasis</arm_group_label>
    <arm_group_label>Restasis and Dextenza</arm_group_label>
    <arm_group_label>Restasis and Lotemax</arm_group_label>
    <other_name>Restasis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loteprednol Etabonate</intervention_name>
    <description>Used to treat inflammation of the eye</description>
    <arm_group_label>Restasis and Lotemax</arm_group_label>
    <other_name>Lotemax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone Ophthalmic 0.4 Mg Ophthalmic Insert</intervention_name>
    <description>Used to treat inflammation of the eye</description>
    <arm_group_label>Restasis and Dextenza</arm_group_label>
    <other_name>Dextenza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Signs and symptoms of DED&#xD;
&#xD;
          -  Consent to treat with topical immunomodulator&#xD;
&#xD;
          -  Willing and able to comply with clinic visits and study related procedures&#xD;
&#xD;
          -  Willing and able to sign the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients under the age of 18.&#xD;
&#xD;
          -  Pregnancy (must be ruled out in women of child-bearing age with pregnancy test)&#xD;
&#xD;
          -  Active infectious systemic disease&#xD;
&#xD;
          -  Active infectious ocular or extraocular disease&#xD;
&#xD;
          -  Altered nasolacrimal flow of either acquired, induced, or congenital origin&#xD;
&#xD;
          -  Hypersensitivity to dexamethasone&#xD;
&#xD;
          -  Patients who have been on topical immunomodulating agents in the previous 3 months to&#xD;
             their baseline visit&#xD;
&#xD;
          -  Patient being treated with either topical, oral, or intravenous immunosuppressive&#xD;
             agents, immunomodulating agents, or steroid (including NSAIDS)&#xD;
&#xD;
          -  Patients with severe disease that warrants critical attention, deemed unsafe for the&#xD;
             study by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Erin Kus-Kreidler</last_name>
    <phone>216-503-6535</phone>
    <email>ekus-kreidler@clevelandeyeclinic.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer Penny</last_name>
    <phone>440-526-1974</phone>
    <phone_ext>354</phone_ext>
    <email>jpenny@clevelandeyeclinic.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cleveland Eye Clinic</name>
      <address>
        <city>Brecksville</city>
        <state>Ohio</state>
        <zip>44141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Kus-Kreidler</last_name>
      <phone>216-503-6535</phone>
      <email>ekus-kreidler@clevelandeyeclinic.com</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Penny</last_name>
      <phone>440-526-1974</phone>
      <email>jpenny@clevelandeyeclinic.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 14, 2020</study_first_submitted>
  <study_first_submitted_qc>September 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2020</study_first_posted>
  <last_update_submitted>October 1, 2020</last_update_submitted>
  <last_update_submitted_qc>October 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cleveland Eye Clinic</investigator_affiliation>
    <investigator_full_name>Thomas Chester, OD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loteprednol Etabonate</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

